This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Lori Badura
Head of Global Partnering Rare Disease and Neuroscience at IPSEN

Profile

Current: Vice President, Head of Global Partnering Neuroscience and Rare Disease (October 18-present), leading licensing and collaboration efforts for preclinical and early development strategic initiatives.

Previous:
VP, Global Licensing and Business Development, EMD Serono (October 2013-October, 2021): Identify opportunities for in licensing and partnering on high impact products and innovative approaches that address areas of unmet medical need. Interested in drug and technology platform opportunities at all stages for neurology and immunology, global health, and diagnostics.

NERI: New England Research Institute Principal Research Scientist (May 2013 - Oct 2013): leading business development efforts to build and enhance expertise and clinical excellence around translational medicine and early development opportunities.

Pfizer: Head of Translational Medicine, Neuroscience Research Unit, Pfizer) (2009-2011): leading an innovative group of MD/PhDs to drive decision making in early development programs; Core representative to pre-competitive consortia and external alliances. Expertise in imaging and physiological technology platforms, pharmacogenomic strategies, and innovative clinical study designs.

Translational Medicine clinician in Neuroscience (2007-2009) - clinical lead for programs in neurology and psychiatry driving translational research plans and proof of mechanism studies; clinical lead on drug development programs through Proof of Concept.

Global Portfolio Director for Translational Medicine and Molecular Medicine lines at Pfizer (2005-2007) -coordination of early development portfolio for biomarker and enabling technology efforts across therapeutic areas (allery/respiratory, cardivascular, dermatology, metabolic disorders, pain, CNS. oncology, ophthalmology, inflammation, gastrointestinal, sex health, infectious diseases)

Head of Preclinical Imaging, CPM, Pfizer, (2004-2005): responsible for strategy and deliverables for preclinical imaging portfolio, including MRI, PET, SPECT, MicroCT, Ultrasound, Echocardiology, Radiology, and Gait Analysis approaches. 

Agenda Sessions

  • What’s Next Beyond 2022 – Laying the Groundwork for the Next Decade

    10:00am